Press Release
January 6, 2023

Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs

The UK Life Sciences team advised Synaffix in a licensing agreement with Amgen to develop next generation of antibody-drug conjugates (ADCs) using Synaffix technology.

Under the terms of the agreement, Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments, plus tiered royalties on commercial sales which are consistent with the financials of the recently signed licenses of Synaffix ADC technology platform. Amgen will be responsible for the research, development, manufacturing and commercialization of the ADCs and Synaffix will continue to be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Based in the Netherlands, Synaffix is a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ADCs.

Amgen is a multinational biopharmaceutical company that is engaged in, among other things, the research, development, manufacture and commercialization of pharmaceutical products.

The Goodwin team was led by Malcolm Bates, Lucy Sharples and Beth Ashbridge.

For additional details on the agreement, please read Synaffix’s press release.